Dasiglucagon
Brand names: Zegalogue · Active ingredient: Dasiglucagon
In short: ZEGALOGUE® is indicated for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes aged 6 years and above.
What is Dasiglucagon used for?
ZEGALOGUE® is indicated for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes aged 6 years and above.
Dasiglucagon dosage
ZEGALOGUE autoinjector and prefilled syringe are for subcutaneous injection only.
Instruct patients and their caregivers on the signs and symptoms of severe hypoglycemia. Because severe hypoglycemia requires the help of others to recover, instruct the patient to inform those around them about ZEGALOGUE and its Instructions For Use. Administer ZEGALOGUE as soon as possible when severe hypoglycemia is recognized.
Instruct the patient or caregiver to read the Instructions For Use at the time they receive a prescription for ZEGALOGUE. Emphasize the following instructions to the patient or caregiver:
•Administer ZEGALOGUE according to the printed instructions on the protective case label and the Instructions For Use.
•Visually inspect ZEGALOGUE prior to administration. The solution should appear clear, colorless, and free from particles. If the solution is discolored or contains particulate matter, do not use.
•Administer the injection in the lower abdomen, buttocks, thigh, or outer upper arm.
•Call for emergency assistance immediately after administering the dose.
•If there has been no response after 15 minutes, an additional dose of ZEGALOGUE may be administered while waiting for emergency assistance.
•When the patient has responded to treatment, give oral carbohydrates to restore liver glycogen and prevent recurrence of hypoglycemia.
•Do not attempt to reuse ZEGALOGUE. Each ZEGALOGUE device contains a single dose of dasiglucagon and cannot be reused.
The recommended dose of ZEGALOGUE in adults and pediatric patients aged 6 years and older is 0.6 mg administered by subcutaneous injection into the lower abdomen, buttocks, thigh, or outer upper arm.
If there has been no response after 15 minutes, an additional 0.6 mg dose of ZEGALOGUE from a new device may be administered.
How to take Dasiglucagon — instructions & advice from the label
Advise the patient and family members or caregivers to read the FDA-approved patient labeling (Patient Information and Instructions For Use).
Recognition of Severe Hypoglycemia
Inform patient and family members or caregivers on how to recognize the signs and symptoms of severe hypoglycemia and the risks of prolonged hypoglycemia.
Administration
Review the Patient Information and Instructions For Use with the patient and family members or caregivers.
Serious Hypersensitivity
Inform patients that allergic reactions can occur with glucagon products like ZEGALOGUE. Advise patients to seek immediate medical attention if they experience any symptoms of serious hypersensitivity reactions .
Warnings & precautions
Do not take this medicine if: ZEGALOGUE is contraindicated in patients with:
•Pheochromocytoma because of the risk of substantial increase in blood pressure
•Insulinoma because of the risk of hypoglycemia
ZEGALOGUE is contraindicated in patients with pheochromocytoma because glucagon products may stimulate the release of catecholamines from the tumor . If the patient develops a substantial increase in blood pressure and a previously undiagnosed pheochromocytoma is suspected, 5 to 10 mg of phentolamine mesylate, administered intravenously, has been shown to be effective in lowering blood pressure.
In patients with insulinoma, administration of glucagon products may produce an initial increase in blood glucose; however, ZEGALOGUE administration may directly or indirectly (through an initial rise in blood glucose) stimulate exaggerated insulin release from an insulinoma and cause hypoglycemia. ZEGALOGUE is contraindicated in patients with insulinoma . If a patient develops symptoms of hypoglycemia after a dose of ZEGALOGUE, give glucose orally or intravenously.
Allergic reactions have been reported with glucagon products; these include generalized rash, and in some cases anaphylactic shock with breathing difficulties and hypotension. Advise patients to seek immediate medical attention if they experience any symptoms of serious hypersensitivity reactions.
ZEGALOGUE is effective in treating hypoglycemia only if sufficient hepatic glycogen is present. Patients in states of starvation, with adrenal insufficiency or chronic hypoglycemia may not have adequate levels of hepatic glycogen for ZEGALOGUE administration to be effective. Patients with these conditions should be treated with glucose.
Dasiglucagon side effects
The following important adverse reactions are described elsewhere in the labeling:
•Hypersensitivity and Allergic Reactions
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of ZEGALOGUE cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
In clinical trials, 316 adult patients with type 1 diabetes and 20 pediatric patients with type 1 diabetes were exposed to ZEGALOGUE.
The data in Table 1 reflect exposure of 116 adult patients to ZEGALOGUE in 2 placebo-controlled trials (mean age 40 years). Table 2 reflects exposure of 20 pediatric patients exposed to ZEGALOGUE in a placebo-controlled trial. Eight patients were 7 to 11 years old, and 12 were 12 to 17 years old .
Adverse reaction type | Placebo
(N=53) | Dasiglucagon
(N=116)
% of Patients | % of Patients
Nausea | 4% | 57%
Vomiting | 2% | 25%
Headache | 4% | 11%
Diarrhea | 0% | 5%
Injection site pain | 0% | 2%
Adverse reaction type | Placebo
(N=11) | Dasiglucagon
Age 6-11 years
(N=8) | Dasiglucagon
Age 12-17 years
(N=12) | Dasiglucagon
All
(N=20)
% of Patients | % of Patients | % of Patients | % of Patients
Nausea | 0% | 25% | 92% | 65%
Vomiting | 0% | 25% | 67% | 50%
Headache | 0% | 0% | 17% | 10%
Injection site pain | 0% | 0% | 8% | 5%
Other Adverse Reactions
Other adverse reactions in patients treated with dasiglucagon occurring within 12 hours of treatment include: …
Drug interactions
Beta-Blockers
Clinical Impact: | Patients taking beta-blockers may have a transient increase in pulse and blood pressure when given ZEGALOGUE.
Indomethacin
Clinical Impact: | In patients taking indomethacin, ZEGALOGUE may lose its ability to raise blood glucose or may even produce hypoglycemia.
Warfarin
Clinical Impact: | ZEGALOGUE may increase the anticoagulant effect of warfarin.
About this medicine
ZEGALOGUE contains dasiglucagon hydrochloride, which is a glucagon analog and an antihypoglycemic agent. Dasiglucagon is comprised of 29 amino acids. The molecular formula of dasiglucagon (anhydrous, free-base) is C152H222N38O50, and its molecular mass is 3382 g/mol (anhydrous, free-base). Dasiglucagon hydrochloride has the following chemical structure:
ZEGALOGUE injection is a preservative free, sterile, aqueous, clear, and colorless solution for subcutaneous use in a single-dose prefilled syringe and an autoinjector. Each prefilled syringe and autoinjector contains 0.63 mg of dasiglucagon provided as dasiglucagon hydrochloride, which is a salt with 3 - 5 equivalents of hydrochloride, and contains the following inactive ingredients: 3.82 mg tromethamine, 6.44 mg sodium chloride, and water for injection. Hydrochloric acid and/or sodium hydroxide may have been added to adjust pH to 6.5. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 14704879-872c-4967-8779-04a3bbdfb4e6. Read the full official label on DailyMed.